Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naïve and treated Crohn's disease

Inflammatory Bowel Diseases

Volumn 16, Issue 1, 2010, Pages 76-86

  Beltŕan, Belén ^a   Nos, Pilar ^a   Dasí, Francisco ^b   Iborra, Marisa ^a   Bastida, Guillermo ^a   Martínez, Marcial ^a   O'Connor, José Enrique ^c   Sáez, Guillermo ^d   Moret, Inés ^b   Ponce, Julio ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Antioxidant enzymes; Catalase; Crohn's disease; Mitochondria; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANTIOXIDANT; CATALASE; HYDROGEN PEROXIDE; MALONALDEHYDE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; SUPEROXIDE DISMUTASE;

ADULT; ARTICLE; CELL ORGANELLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LEUKOCYTE; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MORPHOLOGY; OXIDATIVE STRESS; PRIORITY JOURNAL; REMISSION; REPEAT PROCEDURE; SMOKING;

ADULT; ANTIOXIDANTS; CASE-CONTROL STUDIES; CATALASE; CROHN DISEASE; DEOXYGUANOSINE; FEMALE; GRANULOCYTES; HUMANS; HYDROGEN PEROXIDE; LYMPHOCYTES; MALE; MALONDIALDEHYDE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIAL DISEASES; MONOCYTES; OXIDANTS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE;

EID: 74049155086     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21027     Document Type: Article

References (47)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
2. Kruidenier L, Verspaget HW. Oxidative stress as a pathogenic factor in inflammatory bowel disease - radicals or ridiculous? Aliment Pharmacol Ther. 2002;16:1997-2015.
3. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis in inflammatory bowel disease: an epiphenomenon or the cause? Digest Dis Sci. 2007;52:2015-2021.
4. Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet. 1994;344:859-861.
5. Lih-Brody L, Powell SR, Collier KP, et al. Increased oxidative stress and decreased antioxidant defences in mucosa of inflammatory bowel disease. Dig Dis Sci. 1996;41:2078-2086.
6. Kruidenier L, Kuiper I, Lamers CB, et al. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol. 2003;201:28-36.
7. Tüzün A, Erdil A, Volkan I, et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin Biochem. 2002;35:569-572.
8. Rezaie A, Eshghtork A, Zamani M, et al. Alterations in salivary antioxidants, nitric oxide and transforming growth factor-beta 1 in relation to disease activity in Crohn's disease patients. Ann N Y Acad Sci. 2006;1091:110-122.
9. Mulder TPJ, Verspaget HW, Janssens AR, et al. Decrease in two intestinal cooper/zinc containing proteins with antioxidant function in inflammatory bowel disease. Gut. 1991;32:1146-1150.
10. Kruidenier L, Kuiper I, Dujin W, et al. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol. 2003;201:17-27
11. Curnutte JT, Whittes DM, Babior BM. Defective superoxide production by granulocytes from patients with chronic granulomatous disease. N Engl J Med. 1974;290:593-597.
12. Kitahora T, Suzuki K., Asakura H, et al. Active oxygen species generated by monocytes and polymorphonuclear cells in Crohn's disease. Digest Dis Sci. 1988;33:951-955.
13. Keshavarzian A, Banan A, Farhadi A, et al. Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease. Gut. 2003;52:720-728.
14. Kakkar P, Singh BK. Mitochondria: a hub of redox activities and cellular distress control. Mol Cell Biochem. 2007;305:235-253.
15. Soderholm JD, Olaison G, Peterson KH, et al. Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease. Gut. 2002;50:307-313.
16. Restivo ML, Srivastava MD, Schafer IA, et al. Mitochondrial dysfunction in a patient with Crohn's disease. Possible role in pathogenesis. J Pediatr Gastroenterol Nutr. 2004;38:534-538.
17. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6.
18. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36
19. Harvey RF, Bradshaw JM. Measuring Crohn's disease activity. Lancet. 1980;24:1134-1135.
20. Chappell JB, Hansford RG. In: Subcellular components: preparation and fractionation. Birnie GD, ed. London: Butterworths.
21. Hassan H, Fridovich I. Intracellular production of superoxide radical and of hydrogen peroxide by redox active compounds. Arch Biochem Biophys. 1979;196:385-395.
22. Lebel CP, Ischiropoulos H, Bondy SC. Evaluation of the probe 2′,7′dichlorofluorescein as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol. 1992;5:227-231.
23. Kojima H, Nakatsubo N, Kikuchi K, et al. Detection and imaging of nitric oxide with novel fluorescent indicators: diaminofluoresceins. Anal Chem. 1998;70:2446-2453.
24. Scaduto RS, Grotyohann LW. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivates. Biophys J. 1999;76:469-477.
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
26. Wong SHY, Knight JA, Hopfer SM, et al. Lipoperoxides in plasma as measures by liquid-chromatographic separation of malondialdehydethiobarbituric acid adduct. Clin Chem. 1987;33:214-220.
27. Bashir S, Gilmour H, Denman MA, et al. Oxidative DNA damage and cellular sensitivity to oxidative stress in human autoimmune diseases. Ann Rheum Dis. 1993;52:659-666.
28. Wang CC, Chiang YM, Sung SC, et al. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett. 2008;259:82-98.
29. Biagioni C, Favilli F, Catarzi S, et al. Redox state and O2- production in neutrophils of Crohn's disease patients. Exp Biol Med. 2006;231:186-195.
30. Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev. 1979;59:527-605.
31. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigener family: a comparison of the CU-Zn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution and expression. Free Radic Biol Med. 2002;33:337-349.
32. Verspaget HW, Peña AS, Weterman IT, et al. Diminished neutrophil function in Crohn's disease and ulcerative colitis identified by decreased oxidative metabolism and low superoxide dismutase content. Gut. 1988;29:223-228.
33. Barbosa DS, Cecchini R, El Kadri MZ, et al. Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids. Nutrition. 2003;19:837-842.
34. Kruidenier L, Kuiper I, van Dujin W, et al. Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease. J Pathol. 2003;201:7-16.
35. Dugas B, Debré P, Moncada S. Nitric oxide: a vital poison inside the immune and inflammatory network. Res Immunol. 1995;146:664-670.
36. Rachmilewitz D. Increased colonic nitric oxide level in active IBD. Scand J Gastroenterol. 2008;43:638.
37. Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology. 2004;113:427-437.
38. Dijkstra G, Zandvoort AJ, Kobold AC. et al. Increased expression of inducible nitric oxide synthase in circulating monocytes from patients with active inflammatory bowel disease. Scand J Gastroenterol. 2002;37:546-554.
39. Brown GC, Cooper JM. Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS Lett. 1994;356:295-298.
40. Nenoi M, Ichimura S, Mita K, et al. Regulation of the catalase gene promoter by Sp1, CCAAT-recognizing factors and a WT1/Egr-related factor in hydrogen peroxide-resistant HP100 cells. Cancer Res. 2001;61:5885-5894.
41. Bai J, Cederbaum AI. Overexpression of catalase in the mitochondrial or cytosolic compartment increases sensitivity of HepG2 cells to tumor necrosis factor-alpha-induced apoptosis. J Biol Chem. 2000;275:19241-19249.
42. Herrlich B, Bohmer FD. Redox regulation of signal transduction in mammalian cells. Biochem Pharmacol. 2000;59:35-41.
43. Kahl R, Kampkötter A, Wätjen W, et al. Antioxidant enzymes and apoptosis. Drug Metab Rev. 2004;36:747-762.
44. Boirivant M, Marini M, Felice G, et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2-pathway-induced apoptosis. Gastroenterology. 1999;116:557- 565.
45. Yanbaeba DG, Dentener MA, Creutzberg EC, et al. Systemic effects of smoking. Chest. 2007;131:1557-1566.
46. Dincer Y, Erzin Y, Himmetoglu S, et al. Oxidative DNA damage and antioxidant activity in patients with inflammatory bowel disease. Dig Dis Sci. 2007;52:1636-1641.
47. Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol. 2008;14:378-389.